94 related articles for article (PubMed ID: 31756131)
1. Mutational Profile of Driver Genes in Brazilian Melanomas.
Vicente ALSA; Crovador CS; Macedo G; Scapulatempo-Neto C; Reis RM; Vazquez VL
J Glob Oncol; 2019 Nov; 5():1-14. PubMed ID: 31756131
[TBL] [Abstract][Full Text] [Related]
2. Molecular Profile of Subungual Melanoma: A MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT Promoter Status.
Millan-Esteban D; García-Casado Z; Macià A; de la Rosa I; Torrecilla-Vall-Llossera C; Penin RM; Manrique-Silva E; Pellegrini S; Biasin MR; Rizzolo P; Gavillero A; Di Stefani A; Pellegrini C; Requena C; Fargnoli MC; Peris K; Cota C; Menin C; Landi MT; Nagore E
Dermatology; 2024; 240(1):164-169. PubMed ID: 37918362
[TBL] [Abstract][Full Text] [Related]
3. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.
Neville G; Marzario B; Shilling D; Hand CK; Heffron C
Virchows Arch; 2024 Mar; 484(3):475-479. PubMed ID: 38183457
[TBL] [Abstract][Full Text] [Related]
5. Melanoma: What do all the mutations mean?
Davis EJ; Johnson DB; Sosman JA; Chandra S
Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
[TBL] [Abstract][Full Text] [Related]
6. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival.
Amit M; Tam S; Abdelmeguid AS; Roberts DB; Takahashi Y; Raza SM; Su SY; Kupferman ME; DeMonte F; Hanna EY
Br J Cancer; 2017 Jun; 116(12):1564-1571. PubMed ID: 28494469
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.
Zaremba A; Mohr P; Gutzmer R; Meier F; Pföhler C; Weichenthal M; Terheyden P; Forschner A; Leiter U; Ulrich J; Utikal J; Welzel J; Kaatz M; Gebhardt C; Herbst R; Sindrilaru A; Dippel E; Sachse M; Meiss F; Heinzerling L; Haferkamp S; Weishaupt C; Löffler H; Kreft S; Griewank K; Livingstone E; Schadendorf D; Ugurel S; Zimmer L
Eur J Cancer; 2023 Jul; 188():140-151. PubMed ID: 37245442
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.
Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A
Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090
[TBL] [Abstract][Full Text] [Related]
9. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
Forthun RB; Hovland R; Schuster C; Puntervoll H; Brodal HP; Namløs HM; Aasheim LB; Meza-Zepeda LA; Gjertsen BT; Knappskog S; Straume O
Sci Rep; 2019 Nov; 9(1):17471. PubMed ID: 31767937
[TBL] [Abstract][Full Text] [Related]
10. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity.
Newell F; Wilmott JS; Johansson PA; Nones K; Addala V; Mukhopadhyay P; Broit N; Amato CM; Van Gulick R; Kazakoff SH; Patch AM; Koufariotis LT; Lakis V; Leonard C; Wood S; Holmes O; Xu Q; Lewis K; Medina T; Gonzalez R; Saw RPM; Spillane AJ; Stretch JR; Rawson RV; Ferguson PM; Dodds TJ; Thompson JF; Long GV; Levesque MP; Robinson WA; Pearson JV; Mann GJ; Scolyer RA; Waddell N; Hayward NK
Nat Commun; 2020 Oct; 11(1):5259. PubMed ID: 33067454
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
[TBL] [Abstract][Full Text] [Related]
12. NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand.
Jones AM; Ferguson P; Gardner J; Rooker S; Sutton T; Ahn A; Chatterjee A; Bickley VM; Sarwar M; Emanuel P; Kenwright D; Shepherd PR; Eccles MR
Oncotarget; 2016 Jul; 7(27):41017-41030. PubMed ID: 27191502
[TBL] [Abstract][Full Text] [Related]
13. Targeting
Phadke MS; Smalley KSM
J Clin Oncol; 2023 May; 41(14):2661-2664. PubMed ID: 36947724
[No Abstract] [Full Text] [Related]
14. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
Nsengimana J; Laye J; Filia A; O'Shea S; Muralidhar S; Poźniak J; Droop A; Chan M; Walker C; Parkinson L; Gascoyne J; Mell T; Polso M; Jewell R; Randerson-Moor J; Cook GP; Bishop DT; Newton-Bishop J
J Clin Invest; 2018 May; 128(5):2048-2063. PubMed ID: 29664013
[TBL] [Abstract][Full Text] [Related]
15. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation characteristics of primary melanomas with distinct biological behaviour.
Ecsedi S; Hernandez-Vargas H; Lima SC; Vizkeleti L; Toth R; Lazar V; Koroknai V; Kiss T; Emri G; Herceg Z; Adany R; Balazs M
PLoS One; 2014; 9(5):e96612. PubMed ID: 24832207
[TBL] [Abstract][Full Text] [Related]
17. Novel somatic Missense Mutations in Exon 11 of the KIT Gene are Detected in Melanoma.
Palkina N; Tyumentseva A; Ruksha T
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3015-3020. PubMed ID: 37774052
[TBL] [Abstract][Full Text] [Related]
18. The OSUMMER lines: A series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6.
Murphy BM; Jensen DM; Arnold TE; Aguilar-Valenzuela R; Hughes J; Posada V; Nguyen KT; Chu VT; Tsai KY; Burd CJ; Burd CE
Pigment Cell Melanoma Res; 2023 Sep; 36(5):365-377. PubMed ID: 37341054
[TBL] [Abstract][Full Text] [Related]
19. (V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis.
Rae J; Viros A; Hayward R; Bennett DC; Dhomen N; Longley BJ; Reis-Filho JS; Marais R
J Invest Dermatol; 2012 Feb; 132(2):488-91. PubMed ID: 22113477
[No Abstract] [Full Text] [Related]
20. Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients.
Manrique-Silva E; David ME; Maider AM; García-Casado Z; Moro R; Requena C; Través V; Virós A; Kumar R; Nagore E
Pigment Cell Melanoma Res; 2024 May; 37(3):343-351. PubMed ID: 38153178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
